Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REYE's SYNDROME/ASPIRIN WARNING USE BY PRIVATE RETAILERS

Executive Summary

REYE's SYNDROME/ASPIRIN WARNING USE BY PRIVATE RETAILERS is being urged by FDA through letters mailed Aug. 23. In the letter, FDA Com. Young asks retailers of private label aspirin products to join larger aspirin mfrs. to "voluntarily amend your labels and labeling as proposed by the Aspirin Foundation for aspirin and aspirin-containing products" to warn of the possible association with Reye's Syndrome. Young requested the retailers and distributors to "remove from products packaged only for use in children (pediatric products) indication for use in 'flu' " and to add to the labels of all such products the statement: "Warning: Contact a physician before giving this medicine to children, including teenagers, with chicken pox or flu." Retailers and distributors of private label aspirin products are also requested to notify FDA of the actions they take to inform customers about Reye's Syndrome and the use of aspirin products. The commissioner requested retailers to use point-of-sale notices to advise parents and teenagers of Reye's Syndrome. Included with the letter is a copy of the American Reye's syndrome Association/Reye's Syndrome Society/National Reye's Syndrome Foundation poster for use as a point-of-sale warning of Reye's Syndrome. The poster was mailed out to pharmacists Aug. 1 and Sept. 1 and was included as a tearout in the September issue of American Druggist ("The Pink Sheet" Aug. 12, T&G-4).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS008875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel